GYX Stock Overview
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.38 |
| 52 Week High | UK£0.78 |
| 52 Week Low | UK£0.26 |
| Beta | 1.24 |
| 1 Month Change | -12.84% |
| 3 Month Change | 18.01% |
| 1 Year Change | -33.33% |
| 3 Year Change | -31.53% |
| 5 Year Change | 37.68% |
| Change since IPO | 119.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| GYX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.0% | 0.9% | -1.0% |
| 1Y | -33.3% | -27.7% | 2.0% |
Return vs Industry: GYX underperformed the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: GYX underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| GYX volatility | |
|---|---|
| GYX Average Weekly Movement | 17.9% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GYX's share price has been volatile over the past 3 months.
Volatility Over Time: GYX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 12 | James Barder | www.futuramedical.com |
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel.
Futura Medical plc Fundamentals Summary
| GYX fundamental statistics | |
|---|---|
| Market cap | €129.31m |
| Earnings (TTM) | -€7.59m |
| Revenue (TTM) | €3.61m |
35.8x
P/S Ratio-17.0x
P/E RatioIs GYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GYX income statement (TTM) | |
|---|---|
| Revenue | UK£3.10m |
| Cost of Revenue | UK£1.33m |
| Gross Profit | UK£1.77m |
| Other Expenses | UK£8.29m |
| Earnings | -UK£6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 57.22% |
| Net Profit Margin | -210.03% |
| Debt/Equity Ratio | 0% |
How did GYX perform over the long term?
See historical performance and comparison